Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Feb 18;34(1):92-99.
doi: 10.1093/ajh/hpaa166.

Rationale and Design of the Genotype-Blinded Trial of Torasemide for the Treatment of Hypertension (BHF UMOD)

Linsay McCallum  1 , Katriona Brooksbank  1 , Alex McConnachie  2 , Alisha Aman  1 , Stefanie Lip  1 , Jesse Dawson  1 , Iain M MacIntyre  3 , Thomas M MacDonald  4 , David J Webb  3 , Sandosh Padmanabhan  1
Affiliations
Clinical Trial

Rationale and Design of the Genotype-Blinded Trial of Torasemide for the Treatment of Hypertension (BHF UMOD)

Linsay McCallum et al. Am J Hypertens. .

Abstract

Background: Genome-wide association studies have identified single nucleotide polymorphisms (SNPs) near the uromodulin gene (UMOD) affecting uromodulin excretion and blood pressure (BP). Uromodulin is almost exclusively expressed in the thick ascending limb (TAL) of the loop of Henle and its effect on BP appears to be mediated via the TAL sodium transporter, NKCC2. Loop-diuretics block NKCC2 but are not commonly used in hypertension management. Volume overload is one of the primary drivers for uncontrolled hypertension, so targeting loop-diuretics to individuals who are more likely to respond to this drug class, using the UMOD genotype, could be an efficient precision medicine strategy.

Methods: The BHF UMOD Trial is a genotype-blinded, multicenter trial comparing BP response to torasemide between individuals possessing the AA genotype of the SNP rs13333226 and those possessing the G allele. 240 participants (≥18 years) with uncontrolled BP, on ≥1 antihypertensive agent for ≥3 months, will receive treatment with Torasemide, 5 mg daily for 16 weeks. Uncontrolled BP is average home systolic BP (SBP) >135 mmHg and/or diastolic BP >85 mmHg. The primary outcome is the change in 24-hour ambulatory SBP area under the curve between baseline and end of treatment. Sample size was calculated to detect a 4 mmHg difference between groups at 90% power. Approval by West of Scotland Research Ethics Committee 5 (16/WS/0160).

Results: The study should conclude August 2021.

Conclusions: If our hypothesis is confirmed, a genotype-based treatment strategy for loop diuretics would help reduce the burden of uncontrolled hypertension.

Clinical trials registration: https://clinicaltrials.gov/ct2/show/NCT03354897.

Keywords: NKCC2; blood pressure; furosemide; hypertension; loop-diuretic; uromodulin.

PubMed Disclaimer

Figures

Graphical Abstract
Graphical Abstract
Figure 1.
Figure 1.
BHF UMOD study flow chart. Abbreviations: HBP, home blood pressure; ECG, electrocardiogram; HBPM, home blood pressure monitoring.
See this image and copyright information in PMC

Similar articles

  • UMOD Genotype-Blinded Trial of Ambulatory Blood Pressure Response to Torasemide.
    McCallum L, Lip S, McConnachie A, Brooksbank K, MacIntyre IM, Doney A, Llano A, Aman A, Caparrotta TM, Ingram G, Mackenzie IS, Dominiczak AF, MacDonald TM, Webb DJ, Padmanabhan S. McCallum L, et al. Hypertension. 2024 Oct;81(10):2049-2059. doi: 10.1161/HYPERTENSIONAHA.124.23122. Epub 2024 Jul 30. Hypertension. 2024. PMID: 39077768 Free PMC article.
  • Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension.
    Padmanabhan S, Melander O, Johnson T, Di Blasio AM, Lee WK, Gentilini D, Hastie CE, Menni C, Monti MC, Delles C, Laing S, Corso B, Navis G, Kwakernaak AJ, van der Harst P, Bochud M, Maillard M, Burnier M, Hedner T, Kjeldsen S, Wahlstrand B, Sjögren M, Fava C, Montagnana M, Danese E, Torffvit O, Hedblad B, Snieder H, Connell JM, Brown M, Samani NJ, Farrall M, Cesana G, Mancia G, Signorini S, Grassi G, Eyheramendy S, Wichmann HE, Laan M, Strachan DP, Sever P, Shields DC, Stanton A, Vollenweider P, Teumer A, Völzke H, Rettig R, Newton-Cheh C, Arora P, Zhang F, Soranzo N, Spector TD, Lucas G, Kathiresan S, Siscovick DS, Luan J, Loos RJ, Wareham NJ, Penninx BW, Nolte IM, McBride M, Miller WH, Nicklin SA, Baker AH, Graham D, McDonald RA, Pell JP, Sattar N, Welsh P; Global BPgen Consortium; Munroe P, Caulfield MJ, Zanchetti A, Dominiczak AF. Padmanabhan S, et al. PLoS Genet. 2010 Oct 28;6(10):e1001177. doi: 10.1371/journal.pgen.1001177. PLoS Genet. 2010. PMID: 21082022 Free PMC article.
  • Tamm-Horsfall protein/uromodulin deficiency elicits tubular compensatory responses leading to hypertension and hyperuricemia.
    Liu Y, Goldfarb DS, El-Achkar TM, Lieske JC, Wu XR. Liu Y, et al. Am J Physiol Renal Physiol. 2018 Jun 1;314(6):F1062-F1076. doi: 10.1152/ajprenal.00233.2017. Epub 2018 Jan 10. Am J Physiol Renal Physiol. 2018. PMID: 29357410 Free PMC article.
  • Torasemide prolonged release.
    Lyseng-Williamson KA. Lyseng-Williamson KA. Drugs. 2009 Jul 9;69(10):1363-72. doi: 10.2165/00003495-200969100-00006. Drugs. 2009. PMID: 19583454 Review.
  • Uromodulin: from monogenic to multifactorial diseases.
    Scolari F, Izzi C, Ghiggeri GM. Scolari F, et al. Nephrol Dial Transplant. 2015 Aug;30(8):1250-6. doi: 10.1093/ndt/gfu300. Epub 2014 Sep 16. Nephrol Dial Transplant. 2015. PMID: 25228753 Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328:914–921. - PubMed
    1. Iniesta R, Campbell D, Venturini C, Faconti L, Singh S, Irvin MR, Cooper-DeHoff RM, Johnson JA, Turner ST, Arnett DK, Weale ME, Warren H, Munroe PB, Cruickshank K, Padmanabhan S, Lewis C, Chowienczyk P. Gene variants at loci related to blood pressure account for variation in response to antihypertensive drugs between black and white individuals. Hypertension 2019; 74:614–622. - PubMed
    1. Padmanabhan S, Joe B. Towards precision medicine for hypertension: a review of genomic, epigenomic, and microbiomic effects on blood pressure in experimental rat models and humans. Physiol Rev 2017; 97:1469–1528. - PMC - PubMed
    1. Padmanabhan S, Graham L, Ferreri NR, Graham D, McBride M, Dominiczak AF. Uromodulin, an emerging novel pathway for blood pressure regulation and hypertension. Hypertension 2014; 64:918–923. - PubMed
    1. Padmanabhan S, Melander O, Johnson T, Di Blasio AM, Lee WK, Gentilini D, Hastie CE, Menni C, Monti MC, Delles C, Laing S, Corso B, Navis G, Kwakernaak AJ, van der Harst P, Bochud M, Maillard M, Burnier M, Hedner T, Kjeldsen S, Wahlstrand B, Sjögren M, Fava C, Montagnana M, Danese E, Torffvit O, Hedblad B, Snieder H, Connell JM, Brown M, Samani NJ, Farrall M, Cesana G, Mancia G, Signorini S, Grassi G, Eyheramendy S, Wichmann HE, Laan M, Strachan DP, Sever P, Shields DC, Stanton A, Vollenweider P, Teumer A, Völzke H, Rettig R, Newton-Cheh C, Arora P, Zhang F, Soranzo N, Spector TD, Lucas G, Kathiresan S, Siscovick DS, Luan J, Loos RJ, Wareham NJ, Penninx BW, Nolte IM, McBride M, Miller WH, Nicklin SA, Baker AH, Graham D, McDonald RA, Pell JP, Sattar N, Welsh P, Munroe P, Caulfield MJ, Zanchetti A, Dominiczak AF; Global BPgen Consortium Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. PLoS Genet 2010; 6:e1001177. - PMC - PubMed

Publication types

MeSH terms

Associated data